IL42726A - Composition for promotion of protein synthesis and suppression of urea formation in the body - Google Patents

Composition for promotion of protein synthesis and suppression of urea formation in the body

Info

Publication number
IL42726A
IL42726A IL4272673A IL4272673A IL42726A IL 42726 A IL42726 A IL 42726A IL 4272673 A IL4272673 A IL 4272673A IL 4272673 A IL4272673 A IL 4272673A IL 42726 A IL42726 A IL 42726A
Authority
IL
Israel
Prior art keywords
parts
alpha
sodium
acid
composition
Prior art date
Application number
IL4272673A
Other languages
English (en)
Original Assignee
Mackenzie Walser
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mackenzie Walser filed Critical Mackenzie Walser
Publication of IL42726A publication Critical patent/IL42726A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL4272673A 1972-07-13 1973-07-12 Composition for promotion of protein synthesis and suppression of urea formation in the body IL42726A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27098672A 1972-07-13 1972-07-13
US35532773A 1973-04-30 1973-04-30

Publications (1)

Publication Number Publication Date
IL42726A true IL42726A (en) 1977-10-31

Family

ID=26954620

Family Applications (1)

Application Number Title Priority Date Filing Date
IL4272673A IL42726A (en) 1972-07-13 1973-07-12 Composition for promotion of protein synthesis and suppression of urea formation in the body

Country Status (5)

Country Link
JP (1) JPS4950121A (ru)
CA (1) CA1027478A (ru)
DE (1) DE2335215B2 (ru)
FR (1) FR2226993A1 (ru)
IL (1) IL42726A (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2530246A1 (de) * 1975-07-07 1977-01-13 Fresenius Chem Pharm Ind L-aminosaeuregemische fuer parenterale oder orale anwendung
DE2531299A1 (de) * 1975-07-12 1977-01-13 Fresenius Chem Pharm Ind L-amino- und hydroxy- und/oder ketosaeuren enthaltende gemische fuer parenterale oder orale anwendung
DE2636828A1 (de) * 1976-08-16 1978-02-23 Fresenius Chem Pharm Ind L-amonosaeurengemische fuer die behandlung von leberinsuffizienz sowie die herstellung derartiger gemische
SE7806692L (sv) * 1977-07-01 1979-01-02 Pfizer Anvendning for medicinska endamal av vissa fenylglyoxalsyror, estrar och salter derav
US4320146A (en) 1978-03-17 1982-03-16 The Johns Hopkins University Treatment of hepatic and renal disorders with ornithine and arginine salts of branched chain keto acids
US4228099A (en) 1978-03-17 1980-10-14 The Johns Hopkins University Ornithine and arginine salts of branched chain keto acids and uses in treatment of hepatic and renal disorders
US4296127A (en) * 1979-04-18 1981-10-20 The Johns Hopkins University Mixed salts of essential or semi-essential amino acids and nitrogen-free analogs thereof
US4752619A (en) * 1985-12-23 1988-06-21 The Johns Hopkins University Nutritional supplement for treatment of uremia
SE8803143L (sv) * 1988-09-07 1990-03-08 Kabivitrum Ab Alternativa energisubstrat
DE3936319C3 (de) * 1989-11-01 1997-05-07 Bartz Volker Phosphatbinder zur oralen Verabreichung
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
DE3943424A1 (de) * 1989-12-30 1991-07-04 Nephro Medica Pharma Infusions- und injektionsloesung zur intravenoesen verabreichung
RU2013151090A (ru) * 2011-04-18 2015-05-27 Нестек С.А. Питательные композиции, содержащие альфа-гидроксиизокапроновую кислоту и эйкозапентаеновую кислоту

Also Published As

Publication number Publication date
FR2226993B1 (ru) 1977-07-08
JPS4950121A (ru) 1974-05-15
FR2226993A1 (en) 1974-11-22
CA1027478A (en) 1978-03-07
DE2335215A1 (de) 1974-01-31
DE2335215B2 (de) 1979-04-05
AU5794173A (en) 1975-01-16

Similar Documents

Publication Publication Date Title
US4100161A (en) Promotion of protein synthesis and suppression of urea formation in the body by keto analogs of essential amino acids
US4499076A (en) Elemental diets for liver diseases
CA1057198A (en) Composition and method for promotion of protein synthesis and suppression of urea formation in the body utilizing combinations of alpha-hydroxy-acid analogs of amino acids with alpha-keto-acid analogs
US5084482A (en) Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
US6031000A (en) Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
CA2784836C (en) Improved method of administering .beta.-hydroxy-.beta.-methylbutyrate (hmb)
US5053429A (en) Treating inflammatory pain with methionine
JP2009242413A (ja) アミノ酸をベースとする医薬
IL42726A (en) Composition for promotion of protein synthesis and suppression of urea formation in the body
JP2010180244A (ja) 肝癌発生・進展抑制剤
KR920000324A (ko) 필수 지방산 처리법
US4957938A (en) Nutritional formulation for the treatment of renal disease
Jones et al. Oral essential aminoacid and ketoacid supplements in children with chronic renal failure
US4438144A (en) Amino acid preparation and therapy for treatment of stress and injury
KR840003414A (ko) 3-히드록시부탄산 또는 이 산으로부터 유도된 염을 함유하는 약학적 조성물과, 의약품으로 사용할 수 있는 3-히드록시부탄산으로부터 유도된 화합물
CA2972889A1 (en) Mixture of carboxylic acids for treating patients with kidney failure
Blackburn et al. Criteria for choosing amino acid therapy in acute renal failure
JPS62270522A (ja) 尿毒症を治療するための栄養補強物
US4883661A (en) Use of arginine as an lymphokine synergist
BRPI1011103B1 (pt) Composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l- aspártico
Walser Keto acid therapy in chronic renal failure
IL42787A (en) Compositions for promotion of protein synthesis and suppression of urea formation in the body utilizing alpha-hydroxy acid analogs of amino acids
EP0501641A1 (en) L-2-oxothiazolidine-4-carboxylate and glutathion esters for the treatment of hepatic diseases
PT656178E (pt) Composicoes nutricionais para gestao do metabolismo do azoto
GB1575646A (en) Therapeutic compositions and their administration